Therapy and/or prophylaxis of cranial-cerebral trauma, cerebral ischemia or Alzheimer's disease, using frankincense-based active agents, e.g. boswellic acid or hydrogenated derivatives

摘要

The use of frankincense-based active agents (I) (e.g. boswellic acid) or hydrogenated frankincense-based active agents (II) as medicaments for the therapy and/or prophylaxis of cranial-cerebral trauma and/or cerebral ischemia, or also Alzheimer's disease in the case of (II), is new. INDEPENDENT CLAMS are also included for: (1) the use of frankincense (FKI)-based active agents (I) in the production of medicaments for the therapy and/or prophylaxis of cranial-cerebral trauma and/or cerebral ischemia, where (I) are selected from FKI (olibanum), FKI extracts, components contained in FKI (or their derivatives and/or salts), pure boswellic acid (BA) (or its derivatives and/or salts) and herbal extracts containing (BA); and (2) the use of hydrogenated FKI-based active agents (II) in the production of medicaments for the therapy and/or prophylaxis of cerebral ischemia, cranial-cerebral trauma and/or Alzheimer's disease, where (II) are selected from hydrogenation products of FKI extracts, components contained in FKI (or their derivatives and/or salts), pure BA (or its derivatives and/or salts) and herbal extracts containing BA. ACTIVITY : Cerebroprotective; Vulnerary; Neuroprotective; Nootropic. In tests in rats with traumatic brain damage induced by a fluid percussion method, intraperitoneal administration of frankincense extract at 10 mg/kg 6 days after the operation significantly reduced the death of nerve cells in the cortical and striatal regions of the brain (assessed after 7 days). MECHANISM OF ACTION : None given in the source material.